Stephen Aronoff, MD
Endocrinology, Diabetes & Metabolism · Richardson, TXNPI 1538106844
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $185,264 of the $216,768 with a category attached, or 85.5%. Amgen accounts for 82.0% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2019 at $100,775 and has fallen 86.3% since, to $13,758 in 2025. Among endocrinology, diabetes & metabolism clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,062 payments — averaging $204.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$178K
- AstraZeneca$14K
- AbbVie$8K
- Tandem Diabetes Care, Inc.$7K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- plus $7K from 54 others
Across 707 payments — averaging $2206.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$618K
- Novo Nordisk AS$565K
- Boehringer Ingelheim Pharma GmbH & Co.kg$125K
- Boehringer Ingelheim International GmbH$66K
- Sanofi US Services Inc.$64K
- Dexcom, Inc.$54K
- plus $69K from 5 others
What the payments were for
- Consulting fees$4930%
- Speaking & faculty fees$185,26485%
- Travel & lodging$12,7386%
- Food & beverage$17,8678%
- Education$3460%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVENITY$95,967
- Prolia$67,158
- FARXIGA$12,054
- Repatha$8,560
- Synthroid$7,125
- t-slim insulin pump$4,600
- t:slim X2 insulin pump$2,750
- Omnipod$225
- Ozempic$116
- FreeStyle Libre 2$109
How this compares
$216,768 in reported general payments places this provider in the 90th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 280 | $324,000 |
| OzempicSemaglutide | 108 | $145,871 |
| JardianceEmpagliflozin | 56 | $93,010 |
| Enbrel SureclickEtanercept | 12 | $87,916 |
| FarxigaDapagliflozin Propanediol | 48 | $51,676 |
| RybelsusSemaglutide | 25 | $47,919 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 21 | $45,493 |
| Teriparatide | 14 | $36,759 |
| SynthroidLevothyroxine Sodium | 297 | $30,289 |
| JanuviaSitagliptin Phosphate | 21 | $27,948 |
| FiaspInsulin Aspart (Niacinamide) | 11 | $26,993 |
| XareltoRivaroxaban | 22 | $26,837 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $13,794 |
| OmnitropeSomatropin | 18 | $10,903 |
| NexletolBempedoic Acid | 15 | $9,073 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Humalog | $1,187 | $332,044301 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp | $1,358 | $220,783144 claims |
| Boehringer IngelheimJardiance | $286 | $93,01056 claims |
| AstraZenecaFarxiga | $13,860 | $51,67648 claims |
| AbbVieSynthroid, Armour Thyroid | $7,972 | $31,521319 claims |
| MerckJanuvia | $280 | $27,94821 claims |
| Johnson & JohnsonXarelto | $27 | $26,83722 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $259 | $18,13926 claims |
| PfizerLevoxyl | $105 | $2,55852 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Richardson
- Lance SloanLufkin$1.7M
- Pablo MoraDallas$1.3M
- Robert HoodBeaumont$1.3M
- Eduardo LunaEdinburg$1.3M
- Steve FordanDallas$1.2M
- Rosemarie LajaraPlano$1.2M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
- Rocio HarbisonHouston$989K
- Mitchell SorsbyPlano$945K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.